Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

Most patients with advanced melanoma treated with pre-surgical immunotherapy remained alive and free of disease four years post-treatment.

The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world's population and is generally ...

University of Southern California researchers have found a way to rebrand this oft-embarrassing sore subject by genetically ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

Modified Herpes Virus as a Weapon Against Skin Cancer? A new study suggests it might work—even for metastases deep within the ...

Scientists are developing all sorts of potential new treatments to tackle the most difficult cancer cases—including some that ...

The herpes simplex virus type 1 (HSV-1), which affects almost two-thirds of the world's population and is generally ...